Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
WuXi PharmaTech announces winners of third Life Science and Chemistry Awards

WuXi PharmaTech announces winners of third Life Science and Chemistry Awards

CombinatoRx and Neuromed Pharmaceuticals complete merger agreement

CombinatoRx and Neuromed Pharmaceuticals complete merger agreement

CSC completes a Series B financing round

CSC completes a Series B financing round

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Academics and drug companies must work together to win funds for scientific research, says research director

Academics and drug companies must work together to win funds for scientific research, says research director

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Cellular Dynamics International launches iCell Cardiomyocytes

Cellular Dynamics International launches iCell Cardiomyocytes

IDBS included in recent research report from Gartner

IDBS included in recent research report from Gartner

Bio-Quant becomes wholly-owned subsidiary of NexMed

Bio-Quant becomes wholly-owned subsidiary of NexMed

Winners of the 2010 ASBMB-Merck Award

Winners of the 2010 ASBMB-Merck Award

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

YM BioSciences announces results of collaborative antibody development program

YM BioSciences announces results of collaborative antibody development program

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Scientists identify new potential drug for treating acute myeloid leukaemia

Scientists identify new potential drug for treating acute myeloid leukaemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.